When looking for long-term buy and hold investments I believe some of the best options out there are not in the benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO), but can be found outside the index in the lower reaches of the market. Three small-cap shares which I believe could have bright long-term growth prospects are listed below. Here’s why I’m tipping them for big things in the future: The Bionomics Ltd (ASX: BNO) share price has climbed 10% so far this year, building on the strong gains it made last year. The main reason I like this biopharmaceutical company is…
To keep reading, enter your email address or login below.
When looking for long-term buy and hold investments I believe some of the best options out there are not in the benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO), but can be found outside the index in the lower reaches of the market.
Three small-cap shares which I believe could have bright long-term growth prospects are listed below. Here’s why I’m tipping them for big things in the future:
The Bionomics Ltd (ASX: BNO) share price has climbed 10% so far this year, building on the strong gains it made last year. The main reason I like this biopharmaceutical company is its BNC210 anxiety drug. Phase II trials revealed that the drug outperformed the current standard of care with no signs of sedation, memory impairment, addiction, or loss of motor co-ordination. These side effects can occur with the use of benzodiazepines such as Lorazepam. According to management the anxiety disorders market is projected to reach US$18.2 billion per year by 2020.
The ChimpChange Ltd (ASX: CCA) share price is up a staggering 51% year-to-date. This gain is largely the result of the digital banking platform company’s strong growth in customer numbers and total transaction value. In the first-half of FY 2017 the company added an impressive 41,000 customers. This ultimately led to an 85% increase in total transaction volumes in February. With a host of innovative new revenue-generating features on the way, I believe ChimpChange is a company to keep a close eye on.
The LiveHire Ltd (ASX: LVH) share price has jumped 45% so far in 2017. The talent technology company’s shares have been on a tear since the release of a strong quarterly update in January which revealed an impressive 75% quarter-on-quarter increase in cash receipts. LiveHire provides a platform which creates a pool of pre-qualified job candidates for companies to access when they need to recruit. It currently has a host of big name clients including Japara Healthcare Ltd (ASX: JHC) using its service and a hefty cash balance following a $12.5 million capital raising today.
As well as Bionomics, ChimpChange, and LiveHire, I believe these explosive growth shares could be great investments today. I'm tipping each of them to smash the market this year.
For many, blue chip stocks means stability, profitability and regular dividends, often full franked..
But knowing which blue chips to buy, and when, can often be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
If you’re expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you’ll be sorely disappointed. Not only are their dividends growing at a snail’s pace, their profits are under pressure too due to the increasing competitive environment.
The contrast to these “new breed” blue chips couldn’t be greater… especially the very real prospect of significant share price gains, something that’s looking less likely from the usual blue chip suspects.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.